Abstract：Lung cancer is the most common malignancy with the highest morbidity and mortality worldwide, most of which are non-small cell lung cancer (NSCLC).Epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKI) drugs significantly prolonged the survival time of NSCLC patients, but most patients developed drug resistance.Bevacizumab inhibited the activity of human vascular endothelial growth factor and inhibited the formation of blood vessels effectivly, which has better antitumor effect.Bevacizumab and EGFR-TKI drugs act on different tumor growth pathways, and these two drugs have potentially complementary mechanisms to control tumor.The combined treatment of NSCLC has sufficient theoretical basis and application prospect.This article reviews the research progress of Bevacizumab and EGFR-TKI in the treatment of NSCLC.
Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]
Santarpia M，Daffina MG，Karachaliou N，et al.Targeted drugs in small-cell lung cancer[J].Transl Lung Cancer Res，2016，5（1）：51-70.
Li HY，Takayama K，Wang S，et al.Addition of bevacizumab enhances antitumor activity of erlotinib against nonsmall cell lung cancer xenograft depending on VEGF expression[J].Cancer Chemother Pharmacol，2014，74（6）：1297-1305.
[13]
Furugaki K，Fukumura J，Iwai T，et al.Impact of bevacizumab in combination with erlotinb on EGFR-mutated nonsmall cell lung cancer xenograft models with T790M mutation or MET amplification[J].Int J Cancer，2016，138（4）：1024-1032.
[14]
Masuda C，Yanagisawa M，Yorozu K，et al.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFRmutated NSCLC xenograft model[J].Int J Oncol，2017，51（2）：425-434.
Ciuleanu T，Tsai CM，Tsao CJ，et al.A phase Ⅱstudy of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer[J].Lung Cancer，2013，82（2）：276-281.
[17]
Kazushi Y，Yasuhide Y.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer harboring EGFR mutations （JO25567）：an open-label，randomized，multicenter，phase Ⅱstudy[J].Transl Lung Cancer Res，2015，4（3）：217-219.
[18]
Terufumi K，Takashi S，Makoto N，et al.Erlotinib plus bevacizumab phase Ⅱstudy in patients with advanced nonsmall-cell lung cancer （JO25567）：updated safety results[J].Drug Saf，2018，41（2）：229-237.
[19]
Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations （BELIEF）：an international，multicentre，single-arm，phase 2 trial[J].Lancet Respir Med，2017，5（5）：435-444.
[23]
Saito H，Fukuhara T，Furuya N，et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFRpositive advanced non-squamous non-small-cell lung cancer （NEJ026）：interim analysis of an open-label，randomized，multicenter，phase 3 trial[J].Lancet Oncol，2019，20（5）：625-635.
[24]
Yasuhiro C，Masatoshi K，Akihiro T，et al.Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer[J].Ann Transl Med，2018，6（20）：401-407.
[25]
Sakata Y，Kawamura K，Shingu N，et al.Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer[J].Lung Cancer，2016，99（6）：120-122.
京公网安备 11010502046607号